Edgewise Therapeutics Welcomes Michael Nofi as New CFO Amid Leadership Transition
On November 10, 2025, Edgewise Therapeutics, Inc., known for its innovative work in muscle disease therapeutics, announced a significant leadership change. Michael Nofi has been appointed as the Chief Financial Officer (CFO) of the company, succeeding R. Michael Carruthers, who has decided to retire after an impactful five years at Edgewise.
This transition comes at a crucial juncture for Edgewise, as the company is poised to enter a pivotal stage in its development and commercialization efforts. Dr. Kevin Koch, the President and CEO of Edgewise Therapeutics, expressed enthusiasm regarding Nofi’s appointment, emphasizing that Nofi’s extensive financial leadership experience in the biotech realm will be crucial as the company progresses through late-stage development programs.
Nofi's background is remarkably robust, showcasing over 30 years of leadership in finance and accounting within the life sciences industry. Before joining Edgewise, he served as the Chief Accounting Officer at SpringWorks Therapeutics, where his strategic financial insights facilitated the growth and transition of the organization from an R&D-focused entity to a global commercial player. His past roles include significant positions at The Nature's Bounty Co., Acorda Therapeutics, Allergan plc, and Forest Laboratories, further enriching his expertise.
In his new role at Edgewise, Nofi will lead the financial operations and will be responsible for ensuring the company's compliance, accurate financial reporting, and strategic financial planning—all essential elements needed to fuel the company’s growth as it prepares for commercialization.
In acknowledging his predecessor, Dr. Koch highlighted Carruthers' immense contributions over the years, particularly in guiding Edgewise through their IPO and subsequent financing phases. Carruthers’ leadership was instrumental in laying a solid financial foundation, and the company expresses deep gratitude for his service and wishes him the best in his retirement.
Edgewise Therapeutics has garnered a reputation for developing cutting-edge therapeutics aimed at addressing muscular dystrophies and serious cardiac conditions. The company’s flagship products, such as Sevasemten and EDG-7500, are currently in late-stage clinical trials, with the potential to significantly alter treatment paradigms in these challenging medical conditions. Sevasemten is a pioneering oral medication designed to inhibit fast skeletal myosin and has shown promise in treating Becker and Duchenne muscular dystrophies. Additionally, EDG-7500 targets hypertrophic cardiomyopathy, another serious condition affecting heart function, and is in Phase 2 clinical development.
With Michael Nofi on board, Edgewise is strategically positioned to leverage his financial acumen to further its mission of improving the lives of patients and families affected by severe muscle diseases. As the company advances in its clinical trials and prepares to bring its groundbreaking therapies to market, Nofi’s expertise will be pivotal in navigating the financial complexities of biotech commercialization.
For those interested in following Edgewise Therapeutics and staying updated on their progress, more information can be found on their official website or through their social media channels on LinkedIn, X, Facebook, and Instagram.
This transition comes at a crucial juncture for Edgewise, as the company is poised to enter a pivotal stage in its development and commercialization efforts. Dr. Kevin Koch, the President and CEO of Edgewise Therapeutics, expressed enthusiasm regarding Nofi’s appointment, emphasizing that Nofi’s extensive financial leadership experience in the biotech realm will be crucial as the company progresses through late-stage development programs.
Nofi's background is remarkably robust, showcasing over 30 years of leadership in finance and accounting within the life sciences industry. Before joining Edgewise, he served as the Chief Accounting Officer at SpringWorks Therapeutics, where his strategic financial insights facilitated the growth and transition of the organization from an R&D-focused entity to a global commercial player. His past roles include significant positions at The Nature's Bounty Co., Acorda Therapeutics, Allergan plc, and Forest Laboratories, further enriching his expertise.
In his new role at Edgewise, Nofi will lead the financial operations and will be responsible for ensuring the company's compliance, accurate financial reporting, and strategic financial planning—all essential elements needed to fuel the company’s growth as it prepares for commercialization.
In acknowledging his predecessor, Dr. Koch highlighted Carruthers' immense contributions over the years, particularly in guiding Edgewise through their IPO and subsequent financing phases. Carruthers’ leadership was instrumental in laying a solid financial foundation, and the company expresses deep gratitude for his service and wishes him the best in his retirement.
Edgewise Therapeutics has garnered a reputation for developing cutting-edge therapeutics aimed at addressing muscular dystrophies and serious cardiac conditions. The company’s flagship products, such as Sevasemten and EDG-7500, are currently in late-stage clinical trials, with the potential to significantly alter treatment paradigms in these challenging medical conditions. Sevasemten is a pioneering oral medication designed to inhibit fast skeletal myosin and has shown promise in treating Becker and Duchenne muscular dystrophies. Additionally, EDG-7500 targets hypertrophic cardiomyopathy, another serious condition affecting heart function, and is in Phase 2 clinical development.
With Michael Nofi on board, Edgewise is strategically positioned to leverage his financial acumen to further its mission of improving the lives of patients and families affected by severe muscle diseases. As the company advances in its clinical trials and prepares to bring its groundbreaking therapies to market, Nofi’s expertise will be pivotal in navigating the financial complexities of biotech commercialization.
For those interested in following Edgewise Therapeutics and staying updated on their progress, more information can be found on their official website or through their social media channels on LinkedIn, X, Facebook, and Instagram.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.